Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS).
B-cell activating factor
Diet
IgG
Irritable bowel syndrome
Nutrition
Personal food profile
Platelet activating factor
Journal
Nutrition & metabolism
ISSN: 1743-7075
Titre abrégé: Nutr Metab (Lond)
Pays: England
ID NLM: 101231644
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
23
04
2020
accepted:
24
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life. Despite the prevalence of IBS, its etiology and pathophysiology are still to be fully understood, but immune response is known to be involved. In this study, we investigated the variation of two specific cytokines, B-cell activating factor (BAFF) and platelet-activating factor (PAF), the levels of food-specific IgG and the symptom severity, using Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS), following a personalized and unrestricted-calorie diet. We enrolled 30 subjects with diagnosis of IBS, according to Rome-IV criteria, whose inflammatory markers were measured at baseline and after 6 weeks of dietary intervention. The subjects were monitored in a general practice outpatient setting and nutritional advice was offered remotely via two telephone sessions with a nutritionist. BAFF and PAF values did not differ between baseline and end of study, both in compliant (C) and non-compliant (NC) subjects. IgG levels significantly decreased only in compliant subjects: 37.32 (23.24-93.67) IU/mL; 27.9 (7.56-93.96) IU/mL (p = 0.02) and in non-compliant went from 51.83 (13.17-113.1) IU/mL to 44.06 (4.96-255.4) IU/mL (p = 0.97, ns). IBS-SSS significantly decreased in both compliant subjects, from 245 (110-480) to 110 (0-140) (p < 0.0001), and non compliant subjects, from 250 (155-370) to 100 (7-220) (p < 0.0001). Comparing IBS-SSS between week 3 and week 6, only compliant subjects had a significant reduction, from 155 (50-355) to 110 (0-140) (p = 0.005), versus non-compliant, from 115 (35-315) to 100 (7-220) (p = 0.33, ns). These findings support the rapid efficacy and suitability of a personalized dietetic intervention with outside consultation in IBS. ClinicalTrials.gov ID NCT04348760 Registered April 15, 2020 (retrospectively registered) https://clinicaltrials.gov/show/NCT04348760.
Sections du résumé
BACKGROUND
BACKGROUND
Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life. Despite the prevalence of IBS, its etiology and pathophysiology are still to be fully understood, but immune response is known to be involved. In this study, we investigated the variation of two specific cytokines, B-cell activating factor (BAFF) and platelet-activating factor (PAF), the levels of food-specific IgG and the symptom severity, using Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS), following a personalized and unrestricted-calorie diet.
METHODS
METHODS
We enrolled 30 subjects with diagnosis of IBS, according to Rome-IV criteria, whose inflammatory markers were measured at baseline and after 6 weeks of dietary intervention. The subjects were monitored in a general practice outpatient setting and nutritional advice was offered remotely via two telephone sessions with a nutritionist.
RESULTS
RESULTS
BAFF and PAF values did not differ between baseline and end of study, both in compliant (C) and non-compliant (NC) subjects. IgG levels significantly decreased only in compliant subjects: 37.32 (23.24-93.67) IU/mL; 27.9 (7.56-93.96) IU/mL (p = 0.02) and in non-compliant went from 51.83 (13.17-113.1) IU/mL to 44.06 (4.96-255.4) IU/mL (p = 0.97, ns). IBS-SSS significantly decreased in both compliant subjects, from 245 (110-480) to 110 (0-140) (p < 0.0001), and non compliant subjects, from 250 (155-370) to 100 (7-220) (p < 0.0001). Comparing IBS-SSS between week 3 and week 6, only compliant subjects had a significant reduction, from 155 (50-355) to 110 (0-140) (p = 0.005), versus non-compliant, from 115 (35-315) to 100 (7-220) (p = 0.33, ns).
CONCLUSION
CONCLUSIONS
These findings support the rapid efficacy and suitability of a personalized dietetic intervention with outside consultation in IBS.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov ID NCT04348760 Registered April 15, 2020 (retrospectively registered) https://clinicaltrials.gov/show/NCT04348760.
Identifiants
pubmed: 33292297
doi: 10.1186/s12986-020-00528-x
pii: 10.1186/s12986-020-00528-x
pmc: PMC7708901
doi:
Banques de données
ClinicalTrials.gov
['NCT04348760']
Types de publication
Journal Article
Langues
eng
Pagination
101Références
J Neurogastroenterol Motil. 2018 Jul 30;24(3):415-421
pubmed: 29739174
Rheumatology (Oxford). 2013 Jul;52(7):1190-201
pubmed: 23436580
Clin Gastroenterol Hepatol. 2012 Jul;10(7):712-721.e4
pubmed: 22426087
BMC Gastroenterol. 2012 Nov 21;12:166
pubmed: 23170971
JAMA. 2015 Mar 3;313(9):949-58
pubmed: 25734736
PLoS One. 2013;8(1):e53612
pubmed: 23301096
Int J Gen Med. 2018 Jul 06;11:285-291
pubmed: 30013383
Curr Opin Neurobiol. 2020 Jun;62:68-75
pubmed: 31862627
Gastroenterology. 2016 Feb 19;:
pubmed: 27144617
Gastroenterology. 2016 May;150(6):1257-61
pubmed: 27147121
Nat Rev Gastroenterol Hepatol. 2010 Mar;7(3):163-73
pubmed: 20101257
Aliment Pharmacol Ther. 2010 Jul;32(1):66-73
pubmed: 20353497
Scand J Immunol. 2011 Jan;73(1):1-7
pubmed: 21128997
J Neurogastroenterol Motil. 2011 Oct;17(4):349-59
pubmed: 22148103
J Inflamm Res. 2018 Sep 21;11:345-349
pubmed: 30288077
J Immunol. 2016 Jan 1;196(1):196-206
pubmed: 26621863
United European Gastroenterol J. 2015 Apr;3(2):160-5
pubmed: 25922675
Scand J Gastroenterol. 2007 Dec;42(12):1434-9
pubmed: 17852877
Aliment Pharmacol Ther. 1997 Apr;11(2):395-402
pubmed: 9146781
Dig Dis Sci. 2016 Sep;61(9):2608-18
pubmed: 27056038
Nutrients. 2019 May 17;11(5):
pubmed: 31108900
World J Gastroenterol. 2015 Oct 28;21(40):11353-61
pubmed: 26525775